Central Bank & Trust’s NovoCure NVCR Stock Holding History

Central Bank & Trust’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	-$5K	–	277
2019 Q1	$5K	Hold	100	–	–	﹤0.01%	250
2018 Q4	$3K	Buy	+100	New	+$3.66K	﹤0.01%	261

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Central Bank & Trust's NVCR Position: Q2 2019 in Review

Central Bank & Trust sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 100 shares — an estimated $5K sold.

Central Bank & Trust first reported a position in NVCR in Q4 2018 and held it in 2 quarters. The position peaked at $5K in Q1 2019. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

Central Bank & Trust reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
Central Bank & Trust sold 100 NovoCure shares in Q2 2019, an estimated $5K.
Central Bank & Trust first reported a position in NovoCure in Q4 2018 and held it in 2 quarters.
Central Bank & Trust's NovoCure position peaked at $5K in Q1 2019.
197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on Central Bank & Trust's 13F filing for Q2 2019, filed 16 Jul 2019.